Roche Secures FDA CLIA Waiver and CE Mark for Bordetella POC Test
Roche has received CE Mark approval for its first point-of-care test capable of diagnosing and differentiating Bordetella infections, including whooping cough, within 15 minutes. The rapid, PCR-accurate test enables faster clinical decisions and supports early intervention, particularly for vulnerable groups such as infants and the elderly.
Roche Diagnostics | 03/12/2025 | By Dineshwori | 101
Nordic Bioscience, Roche Diagnostics strengthen collaboration for development of biomarkers
Nordic Bioscience will transfer unique and proprietary blood-based biomarkers to Roche Diagnostics to be implemented on the automated COBAS platform<br />
Roche Diagnostics | 17/06/2022 | By Sudeep Soparkar | 730
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy